Status:
COMPLETED
Trimethylamine N-oxide (TMAO) Levels in Periodontal Disease
Lead Sponsor:
Istanbul Medipol University Hospital
Conditions:
Periodontitis
Smoking
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Salivary and serum levels of TMAO and TNF-A can distinguish between individuals with periodontitis and periodontally healthy persons, including smoking and nonsmoking patients.
Detailed Description
Tobacco use is a prevalent global habit with notable impacts on general health and periodontal disease. Trimethylamine N-oxide (TMAO) is a compound involved in the pathogenesis of various systemic inf...
Eligibility Criteria
Inclusion
- • systemically healthy
- clinical diagnosis of periodontitis
- clinical diagnosis of periodontal health
- For smoking group : denied as smoking at least 10 cigarettes per day and the duration should more than 10 years.
Exclusion
- decline to participate and being under 18 \& over 65 years of age; (2) having any systemic inflammatory diseases such as diabetes, rheumatoid arthritis, or systemic conditions, including immunodeficiency syndrome, cardiovascular disorders, or hepatic disorders; (3) the use of antibiotics and/or anti-inflammatory nonsteroidal anti-inflammatory drugs within 3 months preceding the study; (4) having nonsurgical periodontal treatment (previous 6 months); (5)having surgical periodontal treatment (previous 12 months); (6)having \<20 natural teeth excluding the third molars.
Key Trial Info
Start Date :
December 21 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 25 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06580431
Start Date
December 21 2023
End Date
June 25 2024
Last Update
August 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istanbul Medipol University, School of Dentistry
Istanbul, Fatih, Turkey (Türkiye), 34083